Exciting Preclinical Findings for ExoPTEN in Spinal Recovery
NurExone Biologic Inc. is thrilled to announce groundbreaking results from an insightful preclinical study focusing on its innovative product, ExoPTEN. This research demonstrates that a remarkable 100% of small animals treated with a higher dose of ExoPTEN regained significant motor function following spinal cord injury. Utilizing the state-of-the-art CatWalk XT system, researchers meticulously assessed and confirmed these results, marking a pivotal moment for the company.
Study Results: A Testament to ExoPTEN's Efficacy
The study utilized the CatWalk XT system to carefully evaluate the impact of ExoPTEN on the locomotion abilities of the animals. Impressively, all subjects in the higher-dose group exhibited measurable improvements in their walking abilities. In stark contrast, only one animal from the untreated group demonstrated minimal stepping, emphasizing the profound benefits of the treatment.
Dr. Tali Kizhner, the Director of Research and Development at NurExone, remarked, "This is a significant milestone for our program. Witnessing animals regain their ability to walk with noted improvements in locomotion is incredibly exhilarating. The objective data provided by the CatWalk XT strengthens our scientific basis for ExoPTEN’s potential to restore motor function after acute spinal cord injury."
The Study Design: Methodology and Dosing
In the meticulously designed study, researchers administered varying doses of ExoPTEN — mediums and higher single doses — to assess their effect compared to a control group which received only the vehicle injection. The results noted a dose-dependent relationship; 100% of the animals in the high-dose group regained walking abilities in both hind limbs, while 50% of those in the medium-dose group achieved similar results. Meanwhile, only one out of six rats in the untreated control group showed any sign of recovery.
Detailed Gait Analysis Outcomes
The gait analysis provided additional insight, revealing a dose-dependent enhancement in walking functions among treated animals. Notably, those receiving higher doses exhibited expanded paw print areas, greater maximal contact area of their hind paws, a wider base of support, and extended paw walkway contact duration. These measurable improvements reflect enhanced balance, coordination, strength, and overall weight bearing during ambulation.
Next Steps in Research and Regulatory Plans
As NurExone continues to advance its research, the evaluation of other study parameters is still underway. Encouragingly, the higher dose of ExoPTEN was well tolerated with no noticeable side effects reported. The company is poised to initiate further studies aimed at exploring alternative dosing regimens while simultaneously optimizing ExoPTEN’s manufacturing and analytical processes.
These enhancements are designed to refine the therapeutic profile of ExoPTEN and facilitate meaningful discussions with regulatory authorities about forthcoming human trials.
About the CatWalk XT Technology
The CatWalk XT system, developed by Noldus Information Technology, is a leading method for analyzing animal locomotion. This innovative technology employs an illuminated glass walkway to capture detailed movement patterns, enabling researchers to collect accurate, objective data related to motor function.
Commitment to Advancing Treatments for Nervous System Injuries
NurExone's dedication to research and development remains unwavering as it seeks to move forward with ExoPTEN’s dosing strategies, manufacturing methods, and preparations for regulatory submissions. The company is committed to creating new treatment pathways that bring hope to individuals suffering from nervous system injuries.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a biotechnology company listed on the TSX Venture Exchange (TSXV: NRX), OTCQB (OTCQB: NRXBF), and the Frankfurt Stock Exchange (FSE: J90). The company focuses on delivering regenerative therapies using exosome technology to address central nervous system injuries. ExoPTEN, the company's flagship product, has shown impressive preclinical results, indicating strong clinical potential for treating acute spinal cord and optic nerve injuries — markets that are valued in the billions.
With regulatory milestones achieved, such as obtaining the Orphan Drug Designation, NurExone is paving the way towards clinical trials in both the U.S. and Europe. The company is also developing solutions for organizations interested in quality exosomes, providing minimally invasive targeted delivery systems for various conditions.
With a dedicated U.S. subsidiary, Exo-Top Inc., NurExone aims to accelerate its presence and growth in the North American market.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Frequently Asked Questions
1. What are the key findings from the NurExone study?
The study showed that 100% of animals treated with a higher dose of ExoPTEN regained motor function following spinal cord injury.
2. How was the study conducted?
Researchers compared different doses of ExoPTEN in animals and assessed their walking ability using the CatWalk XT system.
3. What is the significance of CatWalk XT in this research?
CatWalk XT provides objective data on animal movement which strengthens the scientific credibility of findings related to ExoPTEN’s efficacy.
4. What plans does NurExone have for future studies?
NurExone plans to explore alternative dosing regimens while continuing to optimize manufacturing processes and prepare for regulatory submissions.
5. What is the main goal of NurExone?
The company aims to develop innovative treatments for nervous system injuries, bringing new hope to affected individuals.
